Abstract
Well-established regional biotech research hubs grew as magnets this year for companies looking to tap ecosystems in which academic and industrial science coexist. No place illustrates that trend better than Boston, home to R&D centers of major drug companies such as Pfizer, Novartis, and Biogen as well as to huge academic and institutional research organizations. Start-ups also come to the city, knowing they can draw on a pool of experienced scientists. This is reflected in data from the Massachusetts Biotechnology Council, whose job postings for chemists have more than tripled since 2010. Of course, not all is rosy. About 120 researchers were put on the job market this year when Merck & Co. closed early-stage research labs it had acquired with Cubist Pharmaceuticals. This was followed by AstraZeneca’s downsizing and spin-off of antibiotics R&D in nearby Lawrence, Mass. Interviews with job hunters earlier this year indicated that most looking for ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
